Online inquiry

IVTScrip™ mRNA-Anti-LOXL2, AB0024(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ762MR)

This product GTTS-WQ762MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets LOXL2 gene. The antibody can be applied in Idiopathic pulmonary fibrosis research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_002318.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4017
UniProt ID Q9Y4K0
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LOXL2, AB0024(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ762MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3906MR IVTScrip™ mRNA-Anti-CD274, BCD-135(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BCD-135
GTTS-WQ11024MR IVTScrip™ mRNA-Anti-CD3E&CLEC12A, MCLA-117(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MCLA-117
GTTS-WQ10464MR IVTScrip™ mRNA-Anti-SOST, LY2541546(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LY2541546
GTTS-WQ5271MR IVTScrip™ mRNA-Anti-IL4-α, CD124(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CD124
GTTS-WQ3962MR IVTScrip™ mRNA-Anti-CD3E&FCRL5, BFCR-4350-A(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BFCR-4350-A
GTTS-WQ10963MR IVTScrip™ mRNA-Anti-IL17A&IL17F, MCAF-5352A(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MCAF-5352A
GTTS-WQ11236MR IVTScrip™ mRNA-Anti-pcrV&psl, MEDI3902(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MEDI3902
GTTS-WQ14347MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG7716(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA RG7716
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW